Serum level of soluble interleukin-2 receptor α correlates with the clinical course and activity of Wilms’ tumour and soft tissue sarcomas in children

References

• Ambrosetti A, Nadali G, Vinante F, Carlini S, Veneri D, Todeschini G, Morosato L, Sabata de D, Chilosi M, Maggi E, Parronchi P, Romagnani S, Semenzato G, Perona G, Pizzolo G. Serum levels of soluble interleukin-2 receptor in Hodgkin disease. Cancer 1993; 72: 201–206
   PubMed Web of Science ®Google Scholar
• Armitage RJ, Lai AP, Roberts PJ, Cawley JC. Certain myeloid cells possess receptors for interleukin-2. British Journal of Haematology 1986; 4: 799–807
   Google Scholar
• Bodey B, Psenko V, Lipsey AL, Kaiser HE. Soluble interleukin-2 receptors in sera of children with primary malignant neoplasms. Anticancer Research 1996; 16: 219–224
   PubMedGoogle Scholar
• Boyano MD, Garcia-Vazquez MD, Gardeazabal J, Garcia de Galdeano A, Smith-Zubiaga I, Canavate ML, Raton JA, Bilbao I, Diaz-Perez JL. Serum-soluble IL-2 receptor and IL-6 levels in patients with melanoma. Oncology 1997; 54: 400–406
   PubMedGoogle Scholar
• Brand JM, Schmucker P, Breidthardt T, Kirchner H. Upregulation of IFN-gamma and soluble interleukin-2 receptor release and altered serum cortisol and prolactin concentration during general anesthesia. Journal of Interferon and Cytokine Research 2001; 21: 793–796
   PubMedGoogle Scholar
• Brivio F, Lissoni P, Mancini D, Tisi E, Tancini G, Barni S, Nociti V. Effect of antitumor surgery on soluble interleukin-2 receptor serum levels. American Journal of Surgery 1991; 161: 466–469
   PubMedGoogle Scholar
• Brunetti G, Bossi A, Baiardi P, Jedrychowska I, Pozzi U, Bacchella L, Bernardo G. Soluble interleukin 2 receptor (sIL2R) in monitoring advanced lung cancer during chemotherapy. Lung Cancer 1999; 23: 1–9
   PubMedGoogle Scholar
• Chilosi M, Semenzato G, Getto G, Ambrosetti A, Fiore-Donati L, Perona G, Berton G, Lestani M, Scarpa A, Agostini C, Trentin L, Zambello R, Masciarelli M, Dazzi F, Vinante F, Caligaris-Cappio F, Pizzolo G. Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: Relationship with the effect of recombinant α-interferon therapy on clinical parameters and natural killer in vitro activity. Blood 1987; 70: 1530–1535
   PubMed Web of Science ®Google Scholar
• Djeu JY, Liu JH, Wei S, Rui H, Pearson CA, Leonard WJ, Blanchard DK. Function associated with IL-2 receptor-β on human neutrophils. Journal of Immunology 1993; 150: 960–970
   PubMedGoogle Scholar
• Espinoza-Delgado I, Ortaldo JR, Winkler-Pickett R, Sugamura K, Varesio L, Longo DL. Expression and role of p75 interleukin 2 receptor on human monocytes. Journal of Experimental Medicine 1990; 171: 1821–1826
   PubMed Web of Science ®Google Scholar
• Fierro MT, Lisa F, Novelli M, Bertero M, Bernengo MG. Soluble interleukin-2 receptor, CD4 and CD8 levels in melanoma: a longitudinal study. Dermatology 1992; 184: 182–190
   PubMedGoogle Scholar
• Gutgsell NS, Malek TR. Formation of high affinity IL-2 receptors is dependent on a nonligand binding region of the α subunit. Journal of Immunology 1994; 153: 3899–3907
   PubMedGoogle Scholar
• Honda M, Kitamura K, Takeshita T, Sugamura K, Tokunaga T. Identification of a soluble IL-2 receptor β-chain from human lymphoid cell line cells. Journal of Immunology 1990; 145: 4131–4135
   PubMed Web of Science ®Google Scholar
• Izzo F, Cremona F, Delrio P, Leonardi E, Castello G, Pignata S, Daniele B, Curley SA. Soluble interleukin-2 receptor levels in hepatocellular cancer: a more sensitive marker than alfa fetoprotein. Annals of Surgical Oncology 1999; 6: 178–185
   PubMedGoogle Scholar
• Janik JE, Morris JC, Pittaluga S, McDonald K, Raffeld M, Jaffe ES, Grant N, Gutierrez M, Waldmann TA, Wilson WH. Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma. Blood 2004; 104: 3355–3357
   PubMed Web of Science ®Google Scholar
• Kallio JP, Tammela TL, Marttinen AT, Kellokumpu-Lehtinen PL. Soluble immunological parameters and early prognosis of renal cell cancer patients. Journal of Experimental and Clinical Cancer Research 2001; 20: 523–528
   PubMedGoogle Scholar
• Kawashima O, Kamiyoshihara M, Sakata S, Endo K, Saito R, Morishita Y. The clinicopathological significance of preoperative serum-soluble interleukin-2 receptor concentrations in operable non-small-cell lung cancer patients. Annals of Surgical Oncology 2000; 7: 239–245
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Imamura M, Hashino S, Noto S, Mori A, Tanaka J, Naohara T, Kasai M, Asaka M. Possible role of granulocyte colony-stimulating factor in increased serum soluble interleukin-2 receptor-α levels after allogenic bone marrow transplantation. Leukemia and Lymphoma 1999; 33: 559–566
   PubMed Web of Science ®Google Scholar
• Komp DM, Shapiro E, McNamara J. Soluble interleukin-2 receptor in childhood non-Hodgkin's lymphoma. Blood 1988; 71: 1172–1174
   PubMedGoogle Scholar
• Komp DM, McNamara J, Buckley P. Elevated soluble interleukin-2 receptor in childhood hemophagocytic histiocytic syndromes. Blood 1989; 73: 2128–2132
   PubMed Web of Science ®Google Scholar
• Marcon L, Rubin LA, Kurman CC, Fritz ME, Longo DL, Uchiyama T, Edwards BK, Nelson DL. Elevated serum levels of soluble tac peptide in adult T-cell leukemia: correlation with clinical status during chemotherapy. Annals of Internal Medicine 1988; 109: 274–279
   PubMed Web of Science ®Google Scholar
• Moon Y, Kim Y, Kim M, Lim J, Kang CS, Kim WI, Shim SI, Chung NG, Park YH, Min WS, Han K. Plasma soluble interleukin-2 receptor (sIL-2R) levels in patients with acute leukemia. Annals of Clinical and Laboratory Science 2004; 34: 410–415
   PubMedGoogle Scholar
• Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T-lymphocytes from normal human bone marrow. Science 1976; 193: 1007–1009
   PubMed Web of Science ®Google Scholar
• Murakami S, Sakata H, Tsuji Y, Okubo K, Hamada S, Hirayama R. Serum soluble interleukin-2 receptor as a predictor of lymph node metastasis in early gastric cancer. Digestive Surgery 2002; 19: 9–15
   PubMedGoogle Scholar
• Murakami S. Soluble interleukin-2 receptor in cancer. Frontiers in Bioscience 2004; 9: 3085–3094
   PubMed Web of Science ®Google Scholar
• Nakase K, Tsuji K, Tamaki S, Tanigawa M, Ikeda T, Miyanishi E, Shiku H. Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies. Cancer Detection and Prevention 2005; 29: 256–259
   PubMedGoogle Scholar
• Naveau S, Balian A, Degos F, Daurat V, Chevret S, Gayno S, Bastie A, Riachi G, Bartolomei-Portal I, Barange K, Moussalli J, Bailly F, Chaumet-Riffaud P, Emilie D. Prognostic value of the soluble interleukin-2 receptor in chronic hepatitis C treated with interferon-alfa. Journal of Hepatology 1999; 31: 612–617
   PubMedGoogle Scholar
• Pavlidis NA, Bairaktari E, Kalef-Ezra J, Nicolaides C, Seferiadis C, Fountzilas G. Serum soluble interleukin-2 receptors in epithelial ovarian cancer patients. International Journal of Biological Markers 1995; 10: 75–80
   PubMedGoogle Scholar
• Peteiro-Cartelle FJ, Alvarez-Jorge A. Dynamic profiles of interleukin-6 and the soluble form of CD25 in burned patients. Burns 1999; 25: 487–491
   PubMed Web of Science ®Google Scholar
• Pui C-H, Ip SH, Kung P, Dodge RK, Berard CW, Crist WM, Murphy SB. High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin's lymphoma. Blood 1987; 70: 624–628
   PubMed Web of Science ®Google Scholar
• Pui C-H, Ip SH, Iflah S, Behm FG, Grose BH, Dodge RK, Crist WM, Furman WL, Murphy SB, Rivera GK. Serum interleukin 2 receptor levels in childhood acute lymphoblastic leukemia. Blood 1988; 71: 1135–1137
   PubMed Web of Science ®Google Scholar
• Pui C-H, Ip SH, Thompson E, Wilimas J, Brown M, Dodge RK, Hoyos de RA, Berard CW, Crist WM. High serum interleukin-2 receptor levels correlate with a poor prognosis in children with Hodgkin's disease. Leukemia 1989; 3: 481–484
   PubMed Web of Science ®Google Scholar
• Pui C-H, Hudson M, Luo X, Wilimas J, Evans W, Crist WM. Serum interleukin-2 receptor levels in Hodgkin disease and other solid tumors of childhood. Leukemia 1993; 7: 1242–1244
   PubMed Web of Science ®Google Scholar
• Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. Journal of Immunology 1985; 135: 3172–3177
   PubMed Web of Science ®Google Scholar
• Rubin LA, Jay G, Nelson DL. The released interleukin 2 receptor binds interleukin 2 efficiently. Journal of Immunology 1986; 137: 3841–3844
   PubMed Web of Science ®Google Scholar
• Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function, and clinical application. Annals of Internal Medicine 1990; 113: 619–627
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Kaminska J, Kowalska M, Ruka W, Steffen J. Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis. International Journal of Cancer 2002; 100: 463–471
   PubMed Web of Science ®Google Scholar
• Schneemilch CE, Bank U. Release of pro- and anti-inflammatory cytokines during different anesthesia procedures. Anaesthesiologie und Reanimation 2001; 26: 4–10
   PubMedGoogle Scholar
• Sakata H, Murakami S, Hirayama R. Serum soluble interleukin-2 receptor (IL-2R) and immunohistochemical staining of IL-2R/Tac antigen in colorectal cancer. International Journal of Clinical Oncology 2002; 7: 312–317
   PubMedGoogle Scholar
• Sedlaczek P, Frydecka I, Gabrys M, Van Dalen A, Einarsson R, Harlozinska A. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Cancer 2002; 95: 1886–1893
   PubMed Web of Science ®Google Scholar
• Sharma S, Saha K, Shinghal RN, Malik GB. Serum soluble interleukin-2 (IL-2) receptor levels in women with breast carcinoma and its correlation with IL-2 receptor expression on blood lymphocytes and lymphocytic infiltration within the tumour. Cancer Immunology, Immunotherapy 1991; 33: 198–202
   PubMedGoogle Scholar
• Shi H-Z, Sun J-J, Pan H-L, Lu J-Q, Zhang J-L, Jiang J-D. Alterations of T-lymphocyte subsets, soluble IL-2 receptor, and IgE in peripheral blood of children with acute asthma attacks. Journal of Allergy and Clinical Immunology 1999; 103: 388–394
   PubMedGoogle Scholar
• Soker M, Colpan L, Ece A, Devecioglu C, Haspolat K. Serum levels of IL-1 beta, sIL-2R, IL-6, IL-8, and TNF-alpha in febrile children with cancer and neutropenia. Medical Oncology 2001; 18: 51–57
   PubMedGoogle Scholar
• Sondel PM. Tumor immunology and pediatric cancer. Principles and Practice of Pediatric Oncology, PA Pizzo, DG Poplack. Lippincott-Raven Publishers, Philadelphia 1997; 103–128
   Google Scholar
• Stasi R, Zinzani PL, Galieni P, Lauta VM, Damasio E, Dispensa E, Dammacco F, Tura S, Papa G. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Cancer 1994; 74: 1792–1800
   PubMed Web of Science ®Google Scholar
• Sugamura K, Takeshita T, Asao H, Kumaki S, Ohbo K, Ohtani K, Nakamura M. IL-2-induced signal transduction: involvement of tyrosine kinase and IL-2 receptor γ chain. Lymphokine Research 1990; 9: 539–547
   PubMedGoogle Scholar
• Tartour E, Mosseri V, Jouffroy T, Deneux L, Jaulerry C, Brunin F, Fridman WH, Rodriguez J. Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. Lancet 2001; 357: 1263–1264
   PubMed Web of Science ®Google Scholar
• Trentin L, Zambello R, Bulian P, Cerutti A, Milani A, Pirone E, Nitti D, Agostini C, Semenzato G. Functional role of IL-2 receptors on tumour-infiltrating lymphocytes. British Journal of Cancer 1994; 69: 1046–1051
   PubMedGoogle Scholar
• Viviani S, Camerini E, Bonfante V, Santoro A, Balzarotti M, Fornier M, Devizzi L, Verderio P, Valagussa P, Bonadonna G. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications. British Journal of Cancer 1998; 77: 992–997
   PubMed Web of Science ®Google Scholar
• Vonderheid EC, Zhang Q, Lessin SR, Polansky M, Abrams JT, Bigler RD, Wasik MA. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology 1998; 38: 207–220
   PubMed Web of Science ®Google Scholar
• Wakao D, Murohashi I, Tominaga K, Yoshida K, Kishimoto K, Yagasaki F, Itoh Y, Itoh K, Sakata T, Kawai N, Kayano H, Suzuki T, Matsuda A, Hirashima K, Bessho M. Serum thymidine kinase and soluble interleukin-2 receptor predict recurrence of malignant lymphoma. Annals of Hematology 2002; 81: 140–146
   PubMed Web of Science ®Google Scholar
• Waldmann TA, Pastan IH, Gansow OA, Junghans RP. The multichain interleukin-2 receptor: a target for immunotherapy. Annals of Internal Medicine 1992; 116: 148–160
   PubMed Web of Science ®Google Scholar
• Wang LS, Chow KC, Li WY, Liu CC, Wu YC, Huang MH. Clinical significance of serum soluble interleukin 2 receptor-alpha in esophageal squamous cell carcinoma. Clinical Cancer Research 2000; 6: 1445–1451
   PubMedGoogle Scholar
• Wu LJ, Chen KY, Chi KH, Chen SY, Liang MJ, Shiau CY, Wang LW, Liu YM, Chow KC, Yen SH. The significance of soluble interleukin-2 receptor in monitoring disease relapse in patients with nasopharyngeal cancer. Japanese Journal of Clinical Oncology 1998; 28: 729–732
   PubMedGoogle Scholar